THERACRYF PLC Logo

THERACRYF PLC

Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.

TCF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVN2C70 (+2 more)
LEI:
213800NO3E6TSTQO8K20
Country:
United Kingdom
Address:
SUITE 24G13 - BLOCK 24, SK10 4TG NETHER ALDERLEY
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

TheraCryf PLC is a clinical-stage therapeutics company developing a new generation of innovative medicines focused on oncology and behavioural brain disorders. The company's pipeline is based on sulforaphane-based therapeutics. TheraCryf's strategy is to advance its drug candidates through clinical trials to generate compelling data, with the objective of partnering its programs with mid-size to large pharmaceutical companies for late-stage development and commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-10 08:00
Regulatory News Service
World Mental Health Day & Q4 Conference Schedule
English 16.5 KB
2025-09-26 16:45
Major Shareholding Notification
Holding(s) in Company
English 23.5 KB
2025-09-08 12:38
Major Shareholding Notification
Holding(s) in Company
English 23.9 KB
2025-09-04 08:00
Regulatory News Service
Ox-1 Patent Grant & Development Programme Update
English 17.3 KB
2025-08-04 16:27
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-07-17 08:00
Regulatory News Service
Manufacturing Scale Up of Lead Ox-1 Programme
English 14.1 KB
2025-07-09 16:07
Post-Annual General Meeting Information
Result of AGM
English 12.3 KB
2025-06-16 17:10
Report Publication Announcement
Notice of AGM
English 13.0 KB
2025-06-10 13:32
Investor Presentation
Ox-1 Investor Presentation
English 11.6 KB
2025-06-03 08:00
Earnings Release
Final results for year to 31 March 2025
English 235.9 KB
2025-05-23 08:14
Report Publication Announcement
Notice of Results and Ox-1 presentation
English 12.5 KB
2025-05-22 13:43
Major Shareholding Notification
Holding(s) in Company
English 52.1 KB
2025-05-16 14:00
Major Shareholding Notification
Holding(s) in Company
English 23.2 KB
2025-03-26 08:00
Investor Presentation
Investor webinar
English 16.2 KB
2025-03-19 13:10
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB

Automate Your Workflow. Get a real-time feed of all THERACRYF PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for THERACRYF PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.